A phase 1/2, open-label study to investigate the safety and efficacy of membrane bound IL15 expressing tumor-infiltrating lymphocytes (OBX-115) in participants with advanced solid tumors

Disease:

Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer

Study phase:

Physician name:

Rodabe Amaria

Department:

Melanoma Medical Oncology

For general questions about clinical trials:

1-844-866-3603